ReviewNucleic acids research2025
ADARs: pleiotropy in function, versatility in application.
Review in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A genome-scale CRISPRi perturbation atlas of human induced pluripotent stem cells.Nature biotechnology · 2026Article
- ADAR-GPT: A continually fine-tuned language model for predicting A-to-I RNA editing sites.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Regulatable In Vivo Gene Expression via Adaptamers.bioRxiv : the preprint server for biology · 2025Article
- Cromolyn as a novel pharmacophore of the Zα domain of the RNA-editing enzyme ADAR1p150.Protein science : a publication of the Protein Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
RNA processing is essential for proper cellular function, contributing to protein and cell state diversity, and is often dysregulated in diseased states. A key subset of RNA regulators is the double-stranded RNA-specific adenosine deaminase (ADAR) protein family, which hydrolytically deaminates double-stranded RNA, causing an adenosine-to-inosine edit (A-to-I). Active ubiquitously throughout the body, this pleiotropic protein family plays critical roles in embryonic patterning, neurological function, and immune regulation. Their aberrant activity has in turn been implicated in a spectrum of disorders, including cancer, metabolic diseases, and autoimmune conditions. By instead purposefully modulating their activity, ADARs have been leveraged to create a versatile toolset for transcriptome engineering. This includes enabling programmable RNA editing, controlled RNA splicing, reversibly modulating protein interactions, and altering cellular inflammation. Here, we review the pleiotropic functions and versatile applications of ADARs, as well as outline areas for growth and potential new avenues in both therapeutics and research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.